Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models

Annals of Neurology

Volumn 65, Issue 4, 2009, Pages 435-447

  Stafstrom, Carl E ^a   Ockuly, Jeffrey C ^a   Murphree, Lauren ^b   Valley, Matthew T ^a   Roopra, Avtar ^a   Sutula, Thomas P ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; BICUCULLINE; DEOXYGLUCOSE; PENTETRAZOLE; ANTICONVULSIVE AGENT; POTASSIUM CHLORIDE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; ELECTRIC SHOCK; ELECTROGRAPHY; EPILEPSY; EPILEPTIC DISCHARGE; GLYCOLYSIS; HIPPOCAMPUS; IN VITRO STUDY; KINDLING; MALE; MOUSE; NONHUMAN; OLFACTORY BULB; PERFORANT NERVE TRACT; PREMEDICATION; PRIORITY JOURNAL; RAT; SEIZURE; ANIMAL; DRUG EFFECT; EVOKED RESPONSE; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; REFLEX EPILEPSY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANTICONVULSANTS; DEOXYGLUCOSE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; EPILEPSY; EPILEPSY, REFLEX; EVOKED POTENTIALS; HIPPOCAMPUS; MALE; MICE; PENTYLENETETRAZOLE; POTASSIUM CHLORIDE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 62949110733     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21603     Document Type: Article

References (55)

1. Vining EPG. Clinical efficacy of the ketogenic diet. Epilepsy Res 1999;37:181-190.
2. Stafstrom CE, Bough KJ. The ketogenic diet for the treatment of epilepsy: a challenge for nutritional neuroscientists. Nutr Neurosci 2003;6:67-79.
3. Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia 2007;48:43-58.
4. Huttenlocher PR. Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy. Pediatr Res 1976;10:536 -540.
5. Sutula TP, Ockuly J, Stafstrom CE, Roopra A. Novel anticonvulsant, antiepileptic properties and favorable toxicology profile of 2-deoxy-D-glucose (2DG) in experimental models of epilepsy. Amer Epil Soc Abstr 4.098, 2006.
6. Garriga-Canut M, Schoenike B, Qazi R, et al. 2-Deoxy-D- glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat Neurosci 2006;9:1382-1387.
7. Wree A. Principles of the 2-deoxyglucose method for the determination of the local cerebral glucose utilization. Eur J Morphol 1990;28:132-138.
8. He XP, Kotloski R, Nef S, et al. Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model. Neuron 2004;43:31-42.
9. Rutecki PA, Lebeda FJ, Johnston D. Epileptiform activity induced by changes in extracellular potassium in hippocampus. J Neurophysiol 1985;54:1363-1374.
10. Traynelis S, Dingledine R. Potassium-induced spontaneous electrographic seizures in the rat hippocampal slice. J Neurophysiol 1988;59:259 -276.
11. Clark S, Wilson WA. Mechanisms of epileptogenesis. Adv Neurol 1999;79:607-630.
12. McBain CJ, Traynelis SF, Dingledine R. High potassium- induced synchronous bursts and electrographic seizures. In: Schwartzkroin PA, ed. Epilepsy: models, mechanisms, and concepts. Cambridge, United Kingdom: Cambridge University Press, 1993:437-461.
13. Chamberlin NL, Dingledine R. Control of epileptiform burst rate by CA3 hippocampal cell afterhyperpolarizations in vitro. Brain Res 1989;492:337-346.
14. Traynelis SF, Dingledine R, McNamara JO, et al. Effect of kindling on potassium-induced electrographic seizures in vitro. Neurosci Lett 1989;105:326 -332.
15. White HS, Johnson M, Wolf H, Kupferberg H. The early identification of anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazole models. Ital J Sci 1995;16:73-77.
16. Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001;47:217-227.
17. Racine RJ. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972;32:281-294.
18. Dzhala VI, Staley KJ. Transition from interictal to ictal activity in limbic networks in vitro. J Neurosci 2003;23:7873-7880.
19. Biagini G, D'Arcangelo G, Baldelli E, et al. Impaired activation of CA3 pyramidal neurons in the epileptic hippocampus. Neuromolecular Med 2005;7:325-342.
20. Biagini G, Baldelli E, Longo D, et al. Proepileptic influence of a focal vascular lesion affecting entorhinal cortex-CA3 connections after status epilepticus. J Neuropath Exp Neurol 2008;67: 687-701.
21. Yee AS, Longacher M, Staley KJ. Convulsant and anticonvul- sant effects of spontaneous CA3 populaiton bursts. J Neurophysiol 2003;89:427-441.
22. Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998;353:191-206.
23. Stables JP, Bertram EH, White HS, et al. Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia 2002;42:1410-1420.
24. White HS. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 2003;44(suppl 7):2.
25. Holmes GL, Zhao Q. Choosing the correct antiepileptic drugs: from animal studies to the clinic. Pediatr Neurol 2008;38: 151-162.
26. Lee J, Bruce-Keller AJ, Kruman Y, et al. 2-Deoxy-D-glucose protects hippocampal neurons against excitotoxic and oxidative injury: evidence for the involvement of stress proteins. J Neurosci Res 1999;57:48-61.
27. Rejdak K, Rejdak R, Sieklucka-Dziuba M, et al. 2-Deoxyglucose enhances epileptic tolerance evoked by transient incomplete brain ischemia in mice. Epilepsy Res 2001;43: 271-278.
28. Laschet JJ, Minier F, Kurcewicz I, et al. Glyceraldehyde-3- phosphate dehydrogenase is a GABA-A receptor kinase linking glycolysis to neuronal inhibition. J Neurosci 2004;24: 7614 -7622.
29. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids 2004;70:309 -319.
30. DeVivo DC, Leckie MP, Ferrendelli JS, McDougal DB. Chronic ketosis and cerebral metabolism. Ann Neurol 1978;3: 331-337.
31. Gasior M, Rogawski MA, Hartman AL. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol 2006;17:431-439.
32. Yudkoff M, Daikhin Y, Nissim I, Nissim I. The ketogenic diet: interactions with brain amino acid handling. In: Stafstrom CE, Rho JM, eds. Epilepsy and the ketogenic diet. Totowa, NJ: Humana Press, 2004:185-199.
33. Sullivan PG, Rippy NA, Dorenbos K, et al. The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann Neurol 2004;55:576-580.
34. Bough KJ, Wetherington J, Hassel B, et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 2006;60:223-235.
35. Cunnane SC, Musa K, Ryan MA, et al. Potential role of poly- unsaturates in seizure protection achieved with the ketogenic diet. Prostaglandins Leukot Essent Fatty Acids 2002;67: 131-135.
36. Cullingford TE. The ketogenic diet; fatty acids, fatty acid- activated receptors and neurological disorders. Prostaglandins Leukot Essent Fatty Acids 2004;70:253-264.
37. Greene AE, Todorova MT, Seyfried TN. Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies. J Neurochem 2003;86: 529-537.
38. Schurr A, West CA, Rigor BM. Lactate-supported synaptic function in the rat hippocampal slice. Science 1988;240: 1326 -1328.
39. Arakawa T, Goto T, Okada Y. Effect of ketone body (D-3- hydroxybutyrate) on neural activity and energy metabolism in hippocampal slices of the adult guinea pig. Neurosci Lett 1991; 130:53-56.
40. Wada H, Okada Y, Nabetani M, Nakamura H. The effects of lactate and beta-hydroxybutyrate on the energy metabolism and neural activity of hippocampal slices from adult and immature rat. Dev Brain Res 1997;101:1-7.
41. Izumi Y, Ishii K, Katsuki H, et al. Beta-hydroxybutyrate fuels synaptic function during development: histological and physiological evidence in rat hippocampal slices. J Clin Invest 1998; 101:1121-1132.
42. Erecinska M, Cherian S, Silver IA. Energy metabolism in mammalian brain during development. Prog Neurobiol 2004;73: 397-445.
43. Leino RL, Gerhart DZ, Duelli R, et al. Diet-induced ketosis increases monocarboxylate transporter (MCT1) levels in rat brain. Neurochem Int 2001;38:519-527.
44. Kirchner A, Veliskova J, Velisek L. Differential effects of low glucose concentrations on seizures and epileptiform activity in vivo and in vitro. Eur J Neurosci 2006;23:1512-1522.
45. Melo TM, Nehlig A, Sonnewald U. Neuronal-glial interactions in rats fed a ketogenic diet. Neurochem Int 2006;48:498 -507.
46. Todorova MT, Tandon P, Madore RA, et al. The ketogenic diet inhibits epileptogenesis in EL mice: a genetic model for idiopathic epilepsy. Epilepsia 2000;41:933-940.
47. Hartman AL, Lyle M, Rogawski MA, Gasior M. Efficacy of the ketogenic diet in the 6-Hz seizure test. Epilepsia 2008;49: 334-339.
48. Hori A, Tandon P, Holmes GL, Stafstrom CE. Ketogenic diet: effects on expression of kindled seizures and behavior in adult rats. Epilepsia 1997;38:750-758.
49. Itoh Y, Abe T, Takaoka R, Tanahashi N. Fluorometric determination of glucose utilization in neurons in vitro and in vivo. J Cereb Blood Flow Metab 2004;24:993-1003.
50. Nehlig A, Coles JA. Cellular pathways of energy metabolism in the brain: is glucose used by neurons or astrocytes? Glia 2007; 55:1238-1250.
51. Simpson IA, Carruthers A, Vannucci SJ. Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab 2007;27:1766-1791.
52. Newman G, Hospod F, Patlak C. Kinetic model of 2-deoxyglucose metabolism using brain slices. J Cereb Blood Flow Metab 1990;10:510-526.
53. Gruetter R. Glycogen: the forgotten cerebral energy store. J Neurosci Res 2003;74:179-183.
54. Aft RL, Zhang FW, Gius D. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer 2002;87:805-812.
55. Mohanti BK, Rath GK, Anantha N, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 1996; 35:103-111.